The Impact of KRAS Status on the Required Surgical Margin Width for Colorectal Liver Metastasis Resection
暂无分享,去创建一个
Hiroyuki Kobayashi | K. Uryuhara | Nobu Oshima | K. Iwaki | S. Kaihara | Kan Toriguchi | M. Kondo | H. Hashida | K. Kitamura | K. Nakao | Tatsuya Koyama | Shotaro Matsuda
[1] D. Zacharoulis,et al. Colorectal Cancer Liver Metastases: Is an R1 Hepatic Resection Accepted? , 2022, Clinics and practice.
[2] A. Benson,et al. Treatment of Metastatic Colorectal Cancer: ASCO Guideline , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] Ryosuke Kita,et al. Indocyanine green plasma clearance rate and 99mTc-galactosyl human serum albumin single-photon emission computed tomography evaluated preoperative remnant liver , 2022, World journal of clinical cases.
[4] S. Faraj,et al. Histopathological factors versus margin size in single colorectal liver metastases: Does a 1-cm margin size matter? , 2022, Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society.
[5] J. Fuster,et al. Impact of microscopic incomplete resection for colorectal liver metastases on surgical margin recurrence: R1‐Contact vs R1 < 1 mm margin width , 2022, Journal of hepato-biliary-pancreatic sciences.
[6] K. Uryuhara,et al. Resection strategy for colorectal liver metastasis focusing on intrahepatic vessels and resection margins , 2021, Surgery Today.
[7] C. Stafford,et al. Infiltrating Tumor Border Configuration is a Poor Prognostic Factor in Stage II and III Colon Adenocarcinoma , 2020, Annals of Surgical Oncology.
[8] I. Zlobec,et al. Tumour budding and its clinical implications in gastrointestinal cancers , 2020, British Journal of Cancer.
[9] J. Hodson,et al. The effects of resection margin and KRAS status on outcomes after resection of colorectal liver metastases. , 2020, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[10] J. García-Foncillas,et al. KRAS and BRAF Mutations as Prognostic and Predictive Biomarkers for Standard Chemotherapy Response in Metastatic Colorectal Cancer: A Single Institutional Study , 2020, Cells.
[11] G. Torzilli,et al. Does KRAS mutation status impact the risk of local recurrence after R1 vascular resection for colorectal liver metastasis? An observational cohort study. , 2019, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[12] Masahiro Yoshida,et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer , 2019, International Journal of Clinical Oncology.
[13] F. Giuliante,et al. The impact of R1 resection for colorectal liver metastases on local recurrence and overall survival in the era of modern chemotherapy: An analysis of 1,428 resection areas , 2019, Surgery.
[14] Prashanth Rawla,et al. Epidemiology of colorectal cancer: incidence, mortality, survival, and risk factors , 2019, Przeglad gastroenterologiczny.
[15] T. Yamanaka,et al. Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study1 , 2018, Neoplasia.
[16] J. Vauthey,et al. RAS Mutation is Associated with Unsalvageable Recurrence Following Hepatectomy for Colorectal Cancer Liver Metastases , 2018, Annals of Surgical Oncology.
[17] T. Pawlik,et al. Impact of Surgical Margin Width on Recurrence and Overall Survival Following R0 Hepatic Resection of Colorectal Metastases: A Systematic Review and Meta-analysis , 2017, Annals of surgery.
[18] E. Ziv,et al. Kras mutation is a marker of worse oncologic outcomes after percutaneous radiofrequency ablation of colorectal liver metastases , 2017, Oncotarget.
[19] Y. Kamatani,et al. Characteristics and prognosis of Japanese colorectal cancer patients: The BioBank Japan Project , 2017, Journal of epidemiology.
[20] J Ricke,et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.
[21] N. Hamdy,et al. Expression of thioredoxin-1 (TXN) and its relation with oxidative DNA damage and treatment outcome in adult AML and ALL: A comparative study , 2016, Hematology.
[22] Hanan H. Rizk,et al. Pretreatment Predictors of Response to PegIFN-RBV Therapy in Egyptian Patients with HCV Genotype 4 , 2016, PloS one.
[23] N. Hamdy,et al. Integrative role of vitamin D related and Interleukin-28B genes polymorphism in predicting treatment outcomes of Chronic Hepatitis C , 2016, BMC Gastroenterology.
[24] K. Muro,et al. Clinical Validation of a Multiplex Kit for RAS Mutations in Colorectal Cancer: Results of the RASKET (RAS KEy Testing) Prospective, Multicenter Study , 2015, EBioMedicine.
[25] S. Truant,et al. Tumour biology of colorectal liver metastasis is a more important factor in survival than surgical margin clearance in the era of modern chemotherapy regimens. , 2015, HPB : the official journal of the International Hepato Pancreato Biliary Association.
[26] N. Gusani,et al. Overall survival by pattern of recurrence following curative intent surgery for colorectal liver metastasis , 2014, Journal of surgical oncology.
[27] C. Hsieh,et al. Hepatic hemodynamic changes during liver transplantation: a review. , 2014, World journal of gastroenterology.
[28] M. Tez,et al. Role of surgery in colorectal cancer liver metastases. , 2014, World journal of gastroenterology.
[29] Viktor H. Koelzer,et al. The Tumor Border Configuration of Colorectal Cancer as a Histomorphological Prognostic Indicator , 2014, Front. Oncol..
[30] Steven A. Curley,et al. RAS Mutation Status Predicts Survival and Patterns of Recurrence in Patients Undergoing Hepatectomy for Colorectal Liver Metastases , 2013, Annals of surgery.
[31] R. Parks,et al. Surgery for Colorectal Liver Metastases , 2013, Digestive Surgery.
[32] Sabine Tejpar,et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. , 2010, The Lancet. Oncology.
[33] M. Jacob,et al. A Rational Approach to Perioperative Fluid Management , 2008, Anesthesiology.
[34] Z. Hamady,et al. Resection margin in patients undergoing hepatectomy for colorectal liver metastasis: a critical appraisal of the 1cm rule. , 2006, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[35] Evelyne M. Loyer,et al. Effect of Surgical Margin Status on Survival and Site of Recurrence After Hepatic Resection for Colorectal Metastases , 2005, Annals of surgery.
[36] Yoshihiro Sakamoto,et al. Genetic and histological assessment of surgical margins in resected liver metastases from colorectal carcinoma: minimum surgical margins for successful resection. , 2002, Archives of surgery.
[37] J. Cuzick,et al. The grading of rectal cancer: historical perspectives and a multivariate analysis of 447 cases , 1986, Histopathology.